13
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Salvianolic acid A attenuates ischemia reperfusion induced rat brain damage by protecting the blood brain barrier through MMP-9 inhibition and anti-inflammation

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Salvianolic acid A (SAA) is a water-soluble component from the root of Salvia Miltiorrhiza Bge, a traditional Chinese medicine, which has been used for the treatment of cerebrovascular diseases for centuries. The present study aimed to determine the brain protective effects of SAA against cerebral ischemia reperfusion injury in rats, and to figure out whether SAA could protect the blood brain barrier (BBB) through matrix metallopeptidase 9 (MMP-9) inhibition. A focal cerebral ischemia reperfusion model was induced by middle cerebral artery occlusion (MCAO) for 1.5-h followed by 24-h reperfusion. SAA was administered intravenously at doses of 5, 10, and 20 mg·kg –1. SAA significantly reduced the infarct volumes and neurological deficit scores. Immunohistochemical analyses showed that SAA treatments could also improve the morphology of neurons in hippocampus CA1 and CA3 regions and increase the number of neurons. Western blotting analyses showed that SAA downregulated the levels of MMP-9 and upregulated the levels of tissue inhibitor of metalloproteinase 1 (TIMP-1) to attenuate BBB injury. SAA treatment significantly prevented MMP-9-induced degradation of ZO-1, claudin-5 and occludin proteins. SAA also prevented cerebral NF- κB p65 activation and reduced inflammation response. Our results suggested that SAA could be a promising agent to attenuate cerebral ischemia reperfusion injury through MMP-9 inhibition and anti-inflammation activities.

          Related collections

          Author and article information

          Journal
          CJNM
          Chinese Journal of Natural Medicines
          Elsevier
          1875-5364
          20 March 2018
          : 16
          : 3
          : 184-193
          Affiliations
          1Beijing Key Laboratory of Drug Target Identification and Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
          2Department of Neuroimmunopharmacology, Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing 100850, China
          Author notes
          *Corresponding author: DU Guan-Hua, E-mail: dugh@ 123456imm.ac.cn

          These authors have no conflict of interest to declare.

          Article
          S1875-5364(18)30046-3
          10.1016/S1875-5364(18)30046-3
          29576054
          Copyright © 2018 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.
          Funding
          Funded by: National Science and Technology Major Projects for “Major New Drugs Innovation and Development”
          Award ID: 2013ZX09508104
          Award ID: 2013ZX09402203
          Funded by: National Natural Science Foundation of China
          Award ID: 81603100
          Funded by: Chinese Academy of Medical Sciences and Peking Union Medical College
          Award ID: 2015-1007-07
          This work was supported by the National Science and Technology Major Projects for “Major New Drugs Innovation and Development” (2013ZX09508104 and 2013ZX09402203), the National Natural Science Foundation of China (No. 81603100), the open project of State Key Laboratory of Toxicology and Medical Counter-measures (TMC201510) and the graduate student innovation fund of Chinese Academy of Medical Sciences and Peking Union Medical College (No. 2015-1007-07).

          Comments

          Comment on this article